BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
BioHarvest Sciences (NASDAQ: BHST) has achieved a significant breakthrough in its Botanical Synthesis platform by successfully producing plant-based exosomes at scale in its bioreactor media. These nano-sized vesicles, naturally secreted by plant cells, offer enhanced absorption and bioavailability compared to regular plant compounds.
The company's bioreactors, which combine optimized growth media with light-permeable technology, produce exosomes containing viniferin, a polyphenol valued for skincare applications. This development positions BioHarvest to enter the global exosome market, projected to grow from $0.7B in 2025 to $2.2B by 2030. The company expects to launch a new skincare application within 18-24 months.
BioHarvest Sciences (NASDAQ: BHST) ha raggiunto una svolta significativa nella sua piattaforma di Sintesi Botanica, producendo con successo esosomi di origine vegetale su scala industriale nel mezzo di coltura dei suoi bioreattori. Queste vescicole nanoscopiche, naturalmente rilasciate dalle cellule vegetali, offrono assorbimento e biodisponibilità superiori rispetto ai normali composti vegetali.
I bioreattori dell'azienda, che combinano un mezzo di crescita ottimizzato con tecnologia a trasmissione luminosa, generano esosomi contenenti viniferina, un polifenolo apprezzato per applicazioni cosmetiche. Questo avanzamento pone BioHarvest nella posizione di entrare nel mercato globale degli esosomi, previsto in crescita da $0.7B nel 2025 a $2.2B entro il 2030. L'azienda prevede di lanciare una nuova applicazione per la cura della pelle entro 18-24 mesi.
BioHarvest Sciences (NASDAQ: BHST) ha conseguido un avance importante en su plataforma de Síntesis Botánica al producir con éxito exosomas vegetales a escala en el medio de sus biorreactores. Estas vesículas nano, secretadas de forma natural por las células vegetales, ofrecen una mejor absorción y biodisponibilidad que los compuestos vegetales convencionales.
Los biorreactores de la compañía, que combinan medios de cultivo optimizados con tecnología permeable a la luz, producen exosomas que contienen viniferina, un polifenol valorado en aplicaciones para el cuidado de la piel. Este desarrollo posiciona a BioHarvest para entrar en el mercado global de exosomas, que se prevé crezca de $0.7B en 2025 a $2.2B para 2030. La compañía espera lanzar una nueva aplicación cosmética en 18-24 meses.
BioHarvest Sciences (NASDAQ: BHST)는 식물 기반 엑소좀을 자사의 바이오리액터 배지에서 대규모로 생산하는 데 성공하며 식물 합성 플랫폼에서 중요한 돌파구를 마련했습니다. 식물 세포가 자연적으로 분비하는 이 나노 크기 소포들은 일반 식물 화합물보다 흡수율과 생체이용률이 향상됩니다.
최적화된 성장 배지와 빛 투과 기술을 결합한 회사의 바이오리액터는 스킨케어에 가치 있는 폴리페놀인 비니페린(viniferin)을 함유한 엑소좀을 생산합니다. 이 개발로 BioHarvest는 글로벌 엑소좀 시장에 진입할 수 있는 위치에 섰으며, 해당 시장은 2025년 $0.7B에서 2030년 $2.2B로 성장할 것으로 예측됩니다. 회사는 18-24개월 내에 새로운 스킨케어 응용 제품을 출시할 계획입니다.
BioHarvest Sciences (NASDAQ: BHST) a réalisé une avancée majeure sur sa plateforme de Synthèse Botanique en produisant avec succès des exosomes d'origine végétale à grande échelle dans le milieu de ses bioréacteurs. Ces vésicules nanométriques, sécrétées naturellement par les cellules végétales, offrent une meilleure absorption et biodisponibilité que les composés végétaux classiques.
Les bioréacteurs de la société, qui allient milieux de culture optimisés et technologie perméable à la lumière, produisent des exosomes contenant la viniférine, un polyphénol apprécié pour les applications de soins de la peau. Cette avancée positionne BioHarvest pour pénétrer le marché mondial des exosomes, qui devrait passer de 0,7 milliard $ en 2025 à 2,2 milliards $ d'ici 2030. La société prévoit de lancer une nouvelle application cosmétique dans 18-24 mois.
BioHarvest Sciences (NASDAQ: BHST) hat einen bedeutenden Durchbruch auf seiner Botanical Synthesis-Plattform erzielt, indem das Unternehmen pflanzenbasierte Exosomen im Maßstab in den Bioreaktor-Medien erfolgreich produziert hat. Diese nanoskaligen Vesikel, die natürlich von Pflanzenzellen ausgeschieden werden, bieten eine bessere Aufnahme und Bioverfügbarkeit als übliche Pflanzenverbindungen.
Die Bioreaktoren des Unternehmens, die optimierte Nährmedien mit lichtdurchlässiger Technologie kombinieren, produzieren Exosomen, die Viniferin enthalten, ein für Hautpflege geschätztes Polyphenol. Diese Entwicklung positioniert BioHarvest für den Eintritt in den globalen Exosom-Markt, der voraussichtlich von $0.7B im Jahr 2025 auf $2.2B bis 2030 wächst. Das Unternehmen plant, innerhalb von 18–24 Monaten eine neue Hautpflegeanwendung einzuführen.
- Successfully produced plant-based exosomes at scale, opening new revenue streams
- Targeting fast-growing exosome market projected to reach $2.2B by 2030
- New skincare product launch expected within 18-24 months
- Technology provides scalable, cost-efficient advantage for CDMO opportunities
- New product launch timeline of 18-24 months indicates significant wait for revenue realization
Insights
BioHarvest's plant exosome breakthrough expands revenue potential and positions them in the growing $2.2B exosome market by 2030.
BioHarvest has achieved a significant technological milestone by successfully producing plant-based exosomes at scale using their proprietary Botanical Synthesis platform. This development represents more than incremental progress—it's a strategic diversification of their product pipeline and revenue potential.
The breakthrough leverages their existing VINIA® bioreactor infrastructure to produce exosomes containing viniferin, creating value through technological synergy rather than requiring entirely new production systems. This efficiency in resource utilization is particularly noteworthy as it suggests favorable economics for this new business vertical.
What makes this development commercially compelling is the dual-path monetization strategy: BioHarvest can develop branded exosome-delivered skincare products and simultaneously pursue CDMO (Contract Development and Manufacturing Organization) opportunities, servicing pharmaceutical and cosmetic companies requiring plant-based exosomes.
The exosome market's projected growth from
The 18-24 month commercialization timeline for skincare applications offers a reasonable horizon for revenue impact, with pharmaceutical applications potentially following as a longer-term opportunity. This development enhances BioHarvest's technological moat through its unique combination of light-permeable bioreactors and optimized growth media that naturally drives high-yield, high-quality exosome production.
The successful scale production of plant-based exosomes represents a particularly compelling opportunity in the premium skincare segment. Viniferin—the polyphenol contained in BioHarvest's exosomes—is already recognized by international cosmetic companies for its anti-aging, firming, brightening, and antioxidant properties, but current delivery systems limit its efficacy.
BioHarvest's innovation addresses the central challenge in skincare formulation: delivery and bioavailability. Their exosome technology provides nano-sized carriers that enhance absorption and bioavailability compared to conventional viniferin formulations. This represents genuine functional differentiation rather than merely marketing positioning.
The skincare market has been shifting toward evidence-based, biotech-derived ingredients with demonstrable efficacy. Premium brands like La Mer, SK-II, and Estée Lauder have built billion-dollar product lines around bioactive compounds with proprietary delivery systems. BioHarvest's exosome technology aligns perfectly with this high-margin segment of the market.
What's particularly notable is the clean, plant-based nature of these exosomes. As consumer preferences continue shifting toward sustainable and non-animal-derived ingredients, BioHarvest's plant-based approach offers distinct advantages over mammalian-derived or synthetic alternatives. This positions their technology favorably with both clean beauty brands and traditional prestige skincare companies looking to enhance their sustainability credentials.
The 18-24 month commercialization timeline for skincare applications is reasonable given the typically shorter regulatory pathway compared to pharmaceutical applications. This could allow BioHarvest to generate revenue from this innovation relatively quickly while pursuing longer-term pharmaceutical partnerships in parallel.
Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO Opportunities
Rehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.
Exosomes are nano-sized extracellular vesicles naturally secreted by plant cells, with bioactive properties with enhanced absorption and bioavailability levels versus regular plant compounds. They are becoming highly sought after in a wide range of therapeutic and cosmetic applications, including targeted drug delivery, tissue regeneration, anti-inflammatory treatments, and advanced skincare formulations.
BioHarvest's bioreactors are designed to do more than grow plant cells—they create the ideal environment for high-yield, high-value exosomes. By combining optimized growth media with light-permeable bioreactors, the BioHarvest system naturally drives cells to release exosomes that are enriched with important metabolites. This unique combination delivers superior yields and superior cargo quality, setting BioHarvest apart from conventional plant or animal-derived systems. The result is a scalable, cost-efficient, and defensible advantage that opens powerful new revenue streams for CDMO customers in cosmetics, health, and pharma.
BioHarvest's exosomes are produced in its large scale VINIA® bioreactors, and contain viniferin, a polyphenol prized for anti-aging, firming, brightening, and antioxidant benefits in skincare applications. Unlike conventional viniferin formulations used by international cosmetic companies, BioHarvest's plant-derived exosomes provide a novel and more efficacious delivery vehicle for viniferin, as their nano-sized structure enhances absorption and bioavailability in the skin compared to conventional formulations.
Ilan Sobel, CEO of BioHarvest Sciences, commented:
"We are always pushing the boundaries of our Botanical Synthesis technology and the capabilities of our bioreactors, and we have now proven that our bioreactors can efficiently produce plant-based exosomes, a high-value class of biomolecules with significant potential in health and cosmetic industries. We expect that within 18 to 24 months, we will be in a position to bring a new, highly differentiated skin care application to the market, using exosomes to carry viniferin in a more efficacious way.
With growing scientific validation and global exosome market demand expected to grow from
BioHarvest Investor Webinar - Today, September 10, 2025, at 1 pm ET
CEO Ilan Sobel will host an online investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below:
Date: Wednesday, September 10, 2025
Time: 1:00 p.m. Eastern time
Webcast link: BHST Virtual Investor Webinar
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that the global exosome market demand will grow, or that a future exosome product will be launched within the next 18-14 months, as launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
*Global Exosomes Market Research Report on Size, Share& Growth Analysis - Mordor Intelligence
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHST@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265842
FAQ
What breakthrough did BioHarvest Sciences (NASDAQ: BHST) announce in September 2025?
How large is the exosome market potential for BioHarvest Sciences?
What are the advantages of BioHarvest's exosome technology?
When will BioHarvest launch its first exosome-based product?
How does BioHarvest produce exosomes in its bioreactors?
